Matches in SemOpenAlex for { <https://semopenalex.org/work/W2115057288> ?p ?o ?g. }
- W2115057288 endingPage "2319" @default.
- W2115057288 startingPage "2309" @default.
- W2115057288 abstract "Abstract The androgen receptor (AR) is a member of a unique class of transcription factors because it contains a ligand-binding domain that, when activated, results in nuclear translocation and the transcriptional activation of genes associated with prostate cancer development. Although androgen deprivation therapies are effective initially for the treatment of prostate cancer, the disease eventually relapses and progresses to castration-resistant prostate cancer (CRPC). Nonetheless, the AR still plays a critical role because late-stage investigational agents that deplete testosterone (abiraterone) or block ligand binding (MDV3100) can still control tumor growth in patients with CRPC. These findings indicate that downmodulation of AR expression may provide a complementary strategy for treating CRPC. In this article, we describe a novel, locked, nucleic acid–based antisense oligonucleotide, designated EZN-4176. When administered as a single agent, EZN-4176 specifically downmodulated AR mRNA and protein, and this was coordinated with inhibition of the growth of both androgen-sensitive and CRPC tumors in vitro as well as in animal models. The effect was specific because no effect on growth was observed with a control antisense oligonucleotide that does not recognize AR mRNA, nor on tumors derived from the PC3, AR-negative, tumor cell line. In addition, EZN-4176 reduced AR luciferase reporter activity in a CRPC model derived from C4-2b cells that were implanted intratibially, indicating that the molecule may control prostate cancer that has metastasized to the bone. These data, together with the continued dependency of CRPC on the AR signaling pathway, justify the ongoing phase I evaluation of EZN-4176 in patients with CRPC. Mol Cancer Ther; 10(12); 2309–19. ©2011 AACR." @default.
- W2115057288 created "2016-06-24" @default.
- W2115057288 creator A5003478119 @default.
- W2115057288 creator A5014632539 @default.
- W2115057288 creator A5024022050 @default.
- W2115057288 creator A5030949210 @default.
- W2115057288 creator A5044451793 @default.
- W2115057288 creator A5044862444 @default.
- W2115057288 creator A5056111788 @default.
- W2115057288 creator A5057037633 @default.
- W2115057288 creator A5058869908 @default.
- W2115057288 creator A5062966348 @default.
- W2115057288 creator A5074179850 @default.
- W2115057288 creator A5081412532 @default.
- W2115057288 creator A5081488428 @default.
- W2115057288 creator A5082926044 @default.
- W2115057288 creator A5084382360 @default.
- W2115057288 creator A5086417693 @default.
- W2115057288 creator A5088977059 @default.
- W2115057288 date "2011-12-01" @default.
- W2115057288 modified "2023-10-17" @default.
- W2115057288 title "Reduced Expression of the Androgen Receptor by Third Generation of Antisense Shows Antitumor Activity in Models of Prostate Cancer" @default.
- W2115057288 cites W1516266951 @default.
- W2115057288 cites W1919512980 @default.
- W2115057288 cites W1972860063 @default.
- W2115057288 cites W1973009327 @default.
- W2115057288 cites W1975609403 @default.
- W2115057288 cites W1980031208 @default.
- W2115057288 cites W1989656600 @default.
- W2115057288 cites W2014303129 @default.
- W2115057288 cites W2015306991 @default.
- W2115057288 cites W2018013724 @default.
- W2115057288 cites W2026162932 @default.
- W2115057288 cites W2027150329 @default.
- W2115057288 cites W2035179289 @default.
- W2115057288 cites W2038660811 @default.
- W2115057288 cites W2039921125 @default.
- W2115057288 cites W2059085904 @default.
- W2115057288 cites W2066857132 @default.
- W2115057288 cites W2083926838 @default.
- W2115057288 cites W2084341407 @default.
- W2115057288 cites W2085847636 @default.
- W2115057288 cites W2089518544 @default.
- W2115057288 cites W2097226696 @default.
- W2115057288 cites W2101606728 @default.
- W2115057288 cites W2108835773 @default.
- W2115057288 cites W2118238803 @default.
- W2115057288 cites W2119504728 @default.
- W2115057288 cites W2123526148 @default.
- W2115057288 cites W2131848867 @default.
- W2115057288 cites W2137201767 @default.
- W2115057288 cites W2139057757 @default.
- W2115057288 cites W2139281532 @default.
- W2115057288 cites W2141255350 @default.
- W2115057288 cites W2142310248 @default.
- W2115057288 cites W2147200519 @default.
- W2115057288 cites W2149131962 @default.
- W2115057288 cites W2156215080 @default.
- W2115057288 cites W2158916045 @default.
- W2115057288 cites W2159689134 @default.
- W2115057288 cites W2161149013 @default.
- W2115057288 cites W2164942212 @default.
- W2115057288 cites W2165782799 @default.
- W2115057288 cites W2165823301 @default.
- W2115057288 cites W2171776498 @default.
- W2115057288 cites W2175470518 @default.
- W2115057288 doi "https://doi.org/10.1158/1535-7163.mct-11-0329" @default.
- W2115057288 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22027692" @default.
- W2115057288 hasPublicationYear "2011" @default.
- W2115057288 type Work @default.
- W2115057288 sameAs 2115057288 @default.
- W2115057288 citedByCount "44" @default.
- W2115057288 countsByYear W21150572882012 @default.
- W2115057288 countsByYear W21150572882013 @default.
- W2115057288 countsByYear W21150572882014 @default.
- W2115057288 countsByYear W21150572882015 @default.
- W2115057288 countsByYear W21150572882016 @default.
- W2115057288 countsByYear W21150572882017 @default.
- W2115057288 countsByYear W21150572882018 @default.
- W2115057288 countsByYear W21150572882019 @default.
- W2115057288 countsByYear W21150572882020 @default.
- W2115057288 countsByYear W21150572882021 @default.
- W2115057288 countsByYear W21150572882022 @default.
- W2115057288 countsByYear W21150572882023 @default.
- W2115057288 crossrefType "journal-article" @default.
- W2115057288 hasAuthorship W2115057288A5003478119 @default.
- W2115057288 hasAuthorship W2115057288A5014632539 @default.
- W2115057288 hasAuthorship W2115057288A5024022050 @default.
- W2115057288 hasAuthorship W2115057288A5030949210 @default.
- W2115057288 hasAuthorship W2115057288A5044451793 @default.
- W2115057288 hasAuthorship W2115057288A5044862444 @default.
- W2115057288 hasAuthorship W2115057288A5056111788 @default.
- W2115057288 hasAuthorship W2115057288A5057037633 @default.
- W2115057288 hasAuthorship W2115057288A5058869908 @default.
- W2115057288 hasAuthorship W2115057288A5062966348 @default.
- W2115057288 hasAuthorship W2115057288A5074179850 @default.
- W2115057288 hasAuthorship W2115057288A5081412532 @default.
- W2115057288 hasAuthorship W2115057288A5081488428 @default.